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➢

Malignant Hyperthermia (MH) is a
rare genetic mutation of the
skeletal muscle that induces a
hypermetabolic response when
patients are exposed to volatile
inhaled anesthetics or depolarizing
neuromuscular blockers (Weant &
Gregory, 2021).

Signs & Symptoms

➢

➢

➢

Symptoms of MH are:
➢

➢
➢

Increased carbon dioxide
production
Hyperthermia
Muscle rigidity

➢

Tachypnea

➢

Acidosis

➢

Hyperkalemia

➢

Rhabdomyolysis

(Weant & Gregory, 2021).

➢

MH is a pharmacogenetic disorder
that is an uncommon but
frequently fatal reaction to inhaled
anesthetics (Zhao et al., 2019).
It causes a rapid rise in body
temperature that is fatal if left
untreated (Zhao et al., 2019).

➢

➢

➢

Triggering Agents
Volatile anesthetic gases:
➢ Desflurane
➢ Sevoflurane
➢ Isoflurane
➢ Halothane
➢ Methoxyflurane.

3.

(Hopkins et al., 2021)
➢

The perioperative team must be aware
of the tasks that are required to manage
MH (Kleidon, 2020).

➢

Dantrolene acts as an antagonist,
binding to a specific region in the
ryanodine receptor 1 (RYR-1) channel. It
reduces the uncontrolled release of
intracellular calcium (Ravaei et al., 2020).

Depolarizing muscle relaxant:
➢ Succinylcholine

➢

(Min et al., 2021)

There is no specific age or
ethnicity MH tends to develop
affect (Amare & Wilson, 2020).

➢

Most reactions were in children
and young adults (Amare &
Wilson, 2020).

➢

Higher prevalence is seen in
males (Amare & Wilson, 2020).

Early
Recognition

Eliminate the triggering agent
Administer intravenous
Dantrolene
Start body cooling

1.
2.

Incidence of MH ranges from
1:5,000 to 1:10,000 with a
mortality rate of 70%-80%
without treatment (Min et al.,
2021).
Early recognition and treatment
with dantrolene and cooling
reduces the mortality rate to
5% (Gallegos & Hennen, 2022).

Priority of treatment is to reverse the
reaction and treat the consequences of
the reaction (Hopkins et al., 2021).
3 ways to reverse the MH process

➢

Significance

Nursing education regarding MH is
critical. Delay in treatment of MH is
associated with increased mortality
and more severe complications
(Hopkins et al., 2021)

➢

MH leads to death in 3 out of 4
cases (Zhao et al., 2019).
For every 20 minutes that
dantrolene administration is
delayed in an MH crisis, mortality
increases by >1% (Gallegos &
Hennen, 2022).

Malignant Hyperthermia Pathophysiology

Initial Nursing Care

Why MH?

Treatment should be aimed at prompt
administration of dantrolene, cooling to
a target core temperature of no more
than 38.5C, hyperventilation, and
supportive measures (Ravaei et al.,
2020).

➢

A pharmacogenetic disorder of skeletal muscle triggered in susceptible
individuals by volatile anesthetics and/or succinylcholine (Riazi et al., 2018).

Post-Reaction
Management
➢

Observe the patient in an intensive
care unit for at least 24 hours (Riazi
et al., 2018).

➢

Reoccurrence of reaction may occur
in 25% of patients requiring further
intervention (Riazi et al., 2018).

Inhalation agents and the depolarizing muscle relaxants trigger:
➢

Calcium stores to be released from the sarcoplasmic reticulum

➢

Uncontrolled entry of calcium from the myoplasm

➢

Activation of biochemical routes related to muscle activation causing the contracture
of skeletal muscles

➢

Glycogenolysis

➢

Increased cellular metabolism

--all of which result in the production of heat, increased lactate level, and acidosis (Ravaei
et al., 2020).
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• Call for Help

➢
MHAUS suggests administering bolus
doses of dantrolene sodium 1 mg/kg
IV every six hours for at least 24
hours or longer as clinically indicated
➢
(Riazi et al., 2018).
Dantrolene can be discontinued or
the interval between doses increased
➢
to every eight or twelve hours if the
core temperature is less than 38C, CK
is declining,, muscle is not rigid, there
is no evidence of myoglobinuria, and
there is metabolic stability for 24
hours (Riazi et al., 2018).
➢
Monitor arterial blood gases, serum
CK, potassium and calcium, urine and
serum myoglobin, and clotting factors
every six hours until they return to
➢
normal (Riazi et al., 2018).
Core temperature should be
continuously monitored until stable
(Riazi et al., 2018).

➢

Counsel the patient and family
regarding MH and the possibility of
MH susceptibility in other family
members (Riazi et al., 2018).

➢

Refer family members to the nearest
MH diagnostic testing center for
testing (Riazi et al., 2018).

Complications
• Administer dantrolene

Prompt
Interventions

• Coo ling measures

• Place urinary cathe ter
• Tre at hyperka le mia & acidosis

Continuing
Care

• Call MHAUS
Hotline

• ICU transfer

The picture above can be used as a quick reference guide for the recognition and
treatment of MH (Gallegos & Hennen, 2022).

➢

.,.....l

The picture above represents the triadic junction of the skeletal muscle and the ryanodine
[Ry1] receptor with its associated proteins (Mullins, 2017).

• 100% Fi 02, discontinue
trigger

➢

Complications of MH include:
➢ Cardiac arrhythmia or arrest (from acidosis and hyperkalemia)
➢ Renal failure
➢ Compartment syndrome
➢ Disseminated intravascular coagulation (DIC)
➢ Pulmonary edema
➢ Central nervous system injury
(Riazi et al., 2018).

➢

Individuals who experienced an MH
episode should have blood sent for
genetic screening of the three
implicated genes (Riazi et al., 2018).

➢

Conclusion &
Implications

Genetics

The phenotype is inherited as an
autosomal dominant trait with
incomplete penetrance and variable
expression (Amare & Wilson, 2020).
The gene can be inherited from either
parent or can be the result of a new
mutation in the affected individual
(Amare & Wilson, 2020).

➢

➢

Affected individuals have a 50% risk of
passing the abnormal gene to their
children (Amare & Wilson, 2020).

➢

The risk of inheritance is the same for
males and females (Amare & Wilson,
2020).

➢

Molecular genetic studies have
established the subtype 1 ryanodine
receptor (RYR1) calcium release
channel gene on chromosome 19 as the
primary locus for MH (Amare & Wilson,
2020).

➢

Mutations in the RYR1 gene account for
most MH cases (Amare & Wilson,
2020).
Another known causative gene is the
CACNA1S gene located on chromosome
1. This gene encodes the alpha-1
subunit of the voltage-gated
dihydropyridine receptor (DHPR)
(Amare & Wilson, 2020).

Episodes of MH are very rare.
However, early recognition and
treatment are required to prevent
death or other serious
complications.
It is crucial that perioperative staff
understand MH and how it is
treated to prevent delays in
treatment.
Dantrolene should be kept in stock
in all facilities that utilize volatile
inhalants or depolarizing muscle
relaxants (Kleidon, 2020).
All patients undergoing general
surgery should complete a preadmission screening regarding MH
history or familial history.
The Malignant Hyperthermia
Association of the U.S. (MHAUS) has
a hotline that should be utilized as a
resource as soon as MH is identified.

MHAUS Hotline
In the United States a ‘‘hotline’’ was
created to provide emergency
assistance (1-800-644-9737) in the
management of MH. The web site of the
MHAUS provides helpful resources
(www.mhaus.org) (Riazi et al., 2018).

Resources

Many different variants causing MH
have been identified in the RYR1 gene
but only a fraction of these meet the
requirements for the causing MH.
(Amare & Wilson, 2020)

Diagnostic Testing
➢

A molecular genetic blood test can
identify MH susceptible individuals

➢

The caffeine-halothane muscle
contracture test remains the gold
standard (Mullins, 2017).

➢

Test results depend on the in vitro
muscle contracture response of
biopsied muscle to graded
concentrations of the calcium
releasing agents of caffeine and
halothane (Mullins, 2017).
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